We are initiating active coverage on OPKO Health (OPK: AMEX) with a Strong Buy-Rating at the current $2 per share range. US-based OPKO is a specialty healthcare company focusing on products for use in ophthalmology and numerous key diseases. OPKO recently acquired the exclusive worldwide rights to a new platform technology for the rapid identification of molecules that can be useful as vaccines and new drugs. As a result, the company is now working toward the development of blood tests for several important diseases including Alzheimer’s, multiple sclerosis, Parkinson’s, and lung cancer.

OPKO is also currently forming a subsidiary in Taiwan to collaborate closely with Academia Sinica – regarded to be the most prestigious academic institution in Taiwan – on the development of a universal flu vaccine. In June, OPKO announced proceeds of around $31 million from a private placement with accredited investors.

OPK shares have been in a solid uptrend of late; the company is well-funded and has plenty of technologies in the pipeline with which to generate positive news. Buy OPKO Health (OPK: AMEX) at current price levels.

<< HOME PAGE | ARCHIVES >>